Compare Abbott Laboratories (ABT) vs Oscar Health Inc (OSCR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Oscar Health Inc — how do they compare? Abbott Laboratories trades at $95.41 (market cap $166.94B), while Oscar Health Inc trades at $31.04 (market cap $9.38B). The key difference: Abbott Laboratories is far larger — about 17.8× Oscar Health Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Oscar Health Inc pays none. Which is the better fit depends on your goals.
| ABT | OSCR | |
|---|---|---|
Market Cap | $166.94B | $9.38B |
Sector | Health | Health |
52-Week High | $136.62 | $32.18 |
52-Week Low | $82.57 | $10.85 |
Enterprise Value | $193.69B | $5.01B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Oscar Health (OSCR) trades at $31.44, down 2.3% on the day but showing strong technical momentum with a bullish moving average signal. The company reported a significant Q1 2026 earnings beat with EPS of $2.07 versus $1.21 expected, though full-year 2025 results showed a net loss of $443 million. Revenue growth remains robust, projected to increase from $11.7 billion in 2025 to $13.3 billion in 2026, while operating cash flow improved substantially.
The outlook is mixed: strong revenue growth and positive cash flow support upside potential, but persistent net losses and negative ROE pose fundamental risks. Analyst consensus is cautious with a $22.50 price target below current levels, indicating skepticism about sustainability despite recent operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
